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Editorial: new insights into the relationship between the
intestine and non-alcoholic fatty liver—is “fatty gut” involved
in disease progression?
Non-alcoholic fatty liver disease (NAFLD) is currently the most
frequent liver disorder worldwide. There is a high heterogeneity in the
natural history of NAFLD, with only a small fraction of patients pro-
gressing to end stage liver disease and/or hepatocellular carcinoma.
This high variability is partly explained by metabolic comorbidities and
genetic risk factors.1 Alteration in the gut microbiota and in the intesti-
nal permeability has also been linked to NAFLD. Robust experimental
data suggest endotoxemia is a trigger for hepatic inflammation leading
to non-alcoholic steatohepatitis (NASH) and NAFLD progression.2,3
However, data from human studies remained controversial.4,5
Pang and coworkers examined the relationship between markers
of endotoxemia and liver damage in patients with NAFLD.6 They
measured circulating levels of Lipopolysaccharide (LPS) and LPS bind-
ing protein (LBP), a stable biomarker reflecting hepatic LPS exposure
in 237 Asian patients with histological NAFLD. First, authors tested
whether endotexemia is associated with liver damage, and found that
LBP was independently associated with hepatocellular damage and
fibrosis, while LPS only with fibrosis. These data lend support to the
hypothesis that endotoxemia is involved in the pathogenesis of
NASH and promotion of fibrogenesis.
Next, they examined the determinants of endotoxemia. LBP
levels were associated with male gender and metabolic risk factors.
Carriers of TM6SF2 rs58542926 C>T, encoding for the E167K loss-
of-function protein variant had also higher LBP levels. The E167K
variant predisposes to NAFLD by impairing apoliprotein B (APOB)
containing lipoprotein secretion by hepatocytes. Indeed, the muta-
tion is associated with reduced fasting circulating lipoprotein concen-
tration.7,8 TM6SF2 silencing in the liver results in steatosis due to
decreased secretion of very low-density lipoproteins (VLDL)-asso-
ciated lipids,7 possibly by decreasing the lipidation of VLDL.9 Impor-
tantly, TM6SF2 is also highly expressed in the intestine, which plays
an important role in post-prandial lipid absorption by secreting chy-
lomicrons, and lipid absorption was modestly impaired in Tm6sf2-/-
mice.9 Therefore, TM6SF2 variant may also reduce the ability to
secrete chylomicrons by enterocytes in humans. In parallel, a reten-
tion of chylomicrons occurs in loss-of-function APOB mutations10
also increasing the risk of to steatosis and progressive liver disease.1
It would thus be tempting to speculate that lipid accumulation in
enterocytes, or “fatty gut” due to the diet, insulin resistance or
genetic factors causes a damage to the epithelial barrier, increased
leaking of bacterial products and consequently liver damage. The
potential mechanism linking the TM6SF2 mutation with endotexemia
and progressive liver damage is presented in Figure 1. To prove this
model enterocyte fat accumulation, increased intestinal permeability
and absorption of intestinal products should be shown in carriers of
the TM6SF2 variant and APOB loss-of-function mutations.
Collectively, these new data are consistent with the hypothesis
that endotoxemia is involved in the pathogenesis of progressive
NAFLD, with potential therapeutic implications. Human genetics may
help shedding light into the relationship between altered intestinal
environment and liver disease.
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F IGURE 1 Putative model for the mechanism linking the TM6SF2
E167K variant and APOB loss-of-function (LOF) mutations with
endotoxemia and progressive NAFLD
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Editorial: hepatitis C direct acting anti-viral agents and the
kidney
The evolution of anti-HCV therapy over the past few years has been
remarkable because of the development of the direct acting antiviral
agents (DAA). The very first DAAs introduced in 2011, specifically,
boceprevir (BOC) and telaprevir (TVR), still required a backbone of
peginterferon and ribavirin (PR). In patients with advanced chronic kid-
ney disease (CKD), however, these treatments were essentially contra-
indicated given the necessity of ribavirin, which causes significant
haemolysis in this clinical setting.1 Sofosbuvir, a pangenotypic NS5B
polymerase inhibitor marked the beginning of the interferon-free,
highly efficacious and well tolerated DAA era. Combination with the
NS5A inhibitors, ledipasvir or velpatasvir, pushed the SVR to 95%-
99%.2 Patients with significant renal dysfunction and/or on dialysis,
however, were still “out of luck”. Sofosbuvir, being renally eliminated,
is contraindicated in patients with advanced CKD (GFR<30 mL/min)3
as pharmacokinetic studies demonstrated a significant increase in the
exposure of sofosbuvir (171%), and its major metabolite, GS-331007
(451%), in patients with severe renal impairment compared to patients
with normal renal function.4 Clinically, in the real world setting, sofos-
buvir treated patients with severe renal impairment more frequently
experienced serious adverse events (19% vs 6%) including acute kid-
ney injury (25% vs 1%).5 Fortunately, other DAA combinations have
been developed that allow these patients access to effective therapy:
grazoprevir with elbasvir6 and glecaprevir with pibrentasvir.7
The question that also should be asked is the nephrotoxic poten-
tial of the DAAs. Recently, in Alimentary Pharmacology and Therapeu-
tics, Maan et al retrospectively examined the renal safety profile of
the first generation PIs, TVR/BOC + PR compared to Sofosbuvir
(SOF) in patients with normal renal function (eGFR>60 mL/min) at
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